Bile acid adsorbent made of imidazole silane-treated silica
The silica-based bile acid adsorbent with an imidazole silane treatment addresses swelling and side effects of conventional adsorbents, enabling effective and comfortable treatment of metabolic diseases.
Patent Information
- Application Number
- JP2020179279
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-10-27
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-10-27
AI Technical Summary
Existing bile acid adsorbents, such as anion exchange resins, suffer from issues like water absorption leading to swelling, unpleasant odor, and side effects, limiting their practical use and requiring high dosages.
A bile acid adsorbent made of silica treated with an organosilicon compound having an imidazole structure, which prevents water absorption and swelling, enhancing adsorption capacity without discomfort or side effects.
The imidazole silane-treated silica adsorbent allows for larger quantities to be taken without swelling or side effects, improving efficacy in treating metabolic diseases.
Smart Images

Figure 0007578945000001 
Figure 0007578945000002 
Figure 0007578945000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a bile acid adsorbent comprising imidazole silane-treated silica. [Background technology]
[0002] In recent years, obesity and associated metabolic diseases such as diabetes have been increasing, posing a major threat not only in terms of their impact on health but also in terms of increasing medical costs. Non-Patent Documents 1 to 3 describe that an increase in the amount of bile acids associated with fat intake affects metabolic diseases such as obesity, type II diabetes, hyperlipidemia, fatty liver, etc. In addition, it has been pointed out that bile acids may be involved in the carcinogenesis of colorectal cancer, the number of patients of which is rapidly increasing.
[0003] In order to prevent or treat these diseases, bile acid adsorbents have been reported that adsorb bile acids that promote fat absorption and promote excretion from the body. In general, basic anion exchange resins are used as bile acid adsorbents, and for example, Patent Document 1 describes an anion exchange resin having an aliphatic quaternary ammonium salt as a functional group. However, anion exchange resin preparations such as cholestyramine have the disadvantage that the dosage is high due to low activity. In addition, anion exchange resins containing quaternary ammonium salts have a foul odor of aliphatic amines and cannot be used in practice as is. In practice, the foul odor is reduced by coating the anion exchange resin, but the surface coating reduces the anion exchange capacity, making it necessary to increase the dosage. On the other hand, there are also issues such as the fact that the drug is difficult to take because it absorbs water and swells, and that it remains in the oral cavity, causing a sense of discomfort, and that it has side effects such as diarrhea, pain, heartburn, and vomiting, so that the dosage is limited and treatment takes a long time.
[0004] Patent Document 2 describes an anion exchange resin having an imidazolyl group that overcomes these problems. Although this anion exchange resin has a higher bile acid adsorption capacity than conventional cholestyramine, the problems of swelling due to water absorption and side effects still remain. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] U.S. Pat. No. 3,499,960 [Patent Document 2] Japanese Patent Application Publication No. 60-209523 [Non-patent literature]
[0006] [Non-Patent Document 1] Jason M. Ridlon et.al., Gut Microbes. 2016, 7(3), 201-215. [Non-Patent Document 2] M. Eslami et.al., Diabet Med. 2020 Oct 6;e14415. [Non-Patent Document 3] Mitsuhiro Watanabe, Diabetes 54(3), 2011, 156-160. Summary of the Invention [Problem to be solved by the invention]
[0007] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a bile acid adsorbent that does not absorb water and swell. [Means for solving the problem]
[0008] As a result of extensive research aimed at achieving the above object, the present inventors have discovered that silica treated with an organosilicon compound having an imidazole structure has a bile acid adsorption effect and does not swell upon absorption of water, thereby completing the present invention.
[0009] That is, the present invention provides 1. A bile acid adsorbent comprising silica particles to which an organosilicon compound represented by the following general formula (1) is bonded: [ka] (In the formula, R 1 , R 2 and R 3 each independently represents a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, a vinyl group, a phenyl group, or a benzyl group; R 4 represents a group represented by the following general formula (2), where R 1 and R 3 may be bonded to form a benzene ring. [ka] (In the formula, A represents a linear or branched divalent linking group which may contain a heteroatom, an ether bond, a urethane bond, a urea bond, a thiourethane bond, and / or a thiourea bond; R 5 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms; R 6 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms, and n represents an integer of 1 to 3. 2. R 4 is any one of groups represented by the following formulas (3) to (12): [ka] (In the formula, m represents an integer of 1 to 12; R 7 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, k represents an integer of 1 to 12, l represents an integer of 1 to 3, R 1 , R 2 , R 3 , R 5 , R 6 and n have the same meaning as above. 3. Formulations containing 1 or 2 bile acid adsorbents and an enteric coating; 4. The formulation of 3, wherein the enteric coating comprises one or more selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, and carboxymethylethylcellulose; 5. Foods containing bile acid sequestrants 1 or 2, 6. Supplements containing 1 or 2 bile acid sequestrants to provide. Effect of the Invention
[0010] The bile acid adsorbent comprising the imidazole silane-treated silica of the present invention does not exhibit swelling upon absorption of water, and therefore causes little discomfort or side effects when taken, and allows the patient to take larger amounts than with conventional preparations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The present invention will be specifically described below. The bile acid adsorbent according to the present invention is characterized in that it comprises silica to which an organosilicon compound represented by general formula (1) is bonded.
[0012] [ka]
[0013] In formula (1), R 1 , R 2 and R 3 each independently represents a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, a vinyl group, a phenyl group, or a benzyl group. 1 and R 3 may be bonded to form a benzene ring. The alkyl group having 1 to 20 carbon atoms may be linear, cyclic, or branched, and specific examples thereof include methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. Among these, R 1 ~R 3 When silica is treated with an aqueous solution, R is preferably a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, and particularly preferably R 1 and R 3 is a hydrogen atom, and R 2 However, an alkyl group having 1 to 3 carbon atoms, in particular, a methyl group, is more preferred.
[0014] Above R 4 represents a group represented by the following general formula (2).
[0015] [ka]
[0016] In formula (2), A represents a linear or branched divalent linking group which may contain a heteroatom such as N, S, O, or Si, a urethane bond, a urea bond, a thiourethane bond, and / or a thiourea bond; R 5 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms; R 6 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms. n represents an integer of 1 to 3, preferably 2 or 3, and more preferably 3.
[0017] Specific examples of the aryl group having 6 to 10 carbon atoms include phenyl, α-naphthyl, and β-naphthyl groups. Specific examples of the alkyl group having 1 to 10 carbon atoms include the above-mentioned R 1 Examples of the groups include the same groups as those exemplified in the above. Among these, R5 is preferably a methyl group or an ethyl group, and R 6 is preferably a methyl group.
[0018] Examples of the divalent linking group A include alkylene groups having 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, and divalent groups having the above heteroatoms, urethane bonds, urea bonds, thiourethane bonds, or thiourea bonds in the chain and / or at the end of the alkylene group. The heteroatoms may be present as substituents of the divalent linking group of the alkylene group, and examples of such substituents include a hydroxyl group, an amino group, an organosilyl group, and an imidazolyl group. When a hydroxyl group is present in the divalent linking group, this hydroxyl group may be bonded to the silicon atom of formula (2) to form a ring structure.
[0019] In the present invention, suitable examples of the group represented by the above formula (2) containing the divalent linking group A include groups represented by the following formulas (3) to (12), but are not limited thereto.
[0020] [ka] (In the formula, R 1 , R 2 , R 3 , R 5 , R 6 and n have the same meaning as above.)
[0021] In the above formulas, R 7 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms. Specific examples of the alkyl group having 1 to 3 carbon atoms include a methyl group, an ethyl group, and an n-propyl group. m represents an integer of 1 to 12, preferably 2 or 3, and more preferably 3. k represents an integer of 1 to 12, preferably 2 or 3, and more preferably 3. l represents an integer of 1 to 3, preferably 2 or 3, and more preferably 3.
[0022] The organosilicon compound can be obtained by reacting an imidazole compound with an organosilicon compound containing an alkoxysilyl group under heating and stirring.
[0023] Specific examples of the imidazole compound include imidazole, 2-methylimidazole, 2-n-propylimidazole, 2-isopropylimidazole, 2-undecylimidazole, 2-phenylimidazole, 2,4-dimethylimidazole, 2-ethyl-4-methylimidazole, 2-phenyl-4-methylimidazole, 1-vinylimidazole, 2-methyl-1-vinylimidazole, 1-allylimidazole, and 1-allyl-2-methylimidazole.
[0024] Specific examples of organosilicon compounds containing an alkoxysilyl group include 3-chloropropyltrimethoxysilane, 3-chloropropylmethyldimethoxysilane, 3-chloropropyltriethoxysilane, 3-isocyanatopropyltrimethoxysilane, 3-isocyanatopropyltriethoxysilane, 3-glycidoxypropyltrimethoxysilane, 3-glycidoxypropylmethyldimethoxysilane, 3-glycidoxypropyltriethoxysilane, 3-methacryloxypropyltrimethoxysilane, 3-methacryloxypropylmethyldimethoxysilane, 3-methacryloxypropyltriethoxysilane, 3-acryloxypropyltrimethoxysilane, 3-acryloxypropylmethyldimethoxysilane, 3-acryloxypropyltriethoxysilane, 3-mercaptopropyltrimethoxysilane, 3-mercaptopropylmethyldimethoxysilane, and 3-mercaptopropyltriethoxysilane.
[0025] The imidazole compound and the organosilicon compound containing an alkoxysilyl group are selected corresponding to the imidazole group and the alkoxysilyl group in the above formula (1), respectively. For example, in the case of an organosilicon compound having a group of the formula (3), 3-chloropropyltrimethoxysilane is selected as the organosilicon compound containing an alkoxysilyl group, and 2-methylimidazole is selected as the imidazole compound.
[0026] A solvent can be used in these reactions. Specific examples of solvents that can be used include hydrocarbon solvents such as pentane, hexane, cyclohexane, heptane, isooctane, benzene, toluene, and xylene; aprotic polar solvents such as N,N-dimethylformamide; and protic polar solvents such as methanol.
[0027] A catalyst can be used in these reactions. For example, when synthesizing an organosilicon compound having a group of the above formula (3), a catalyst generally used in a dehydrochlorination reaction (such as a tertiary amine represented by triethylamine) can be used. In addition, when synthesizing an organosilicon compound having a group of formula (9) or formula (10), a catalyst generally used in a urethane reaction (such as an organotin compound represented by dioctyltin dilaurate) can be used. Furthermore, when synthesizing an organosilicon compound having a group of the above formula (11) or formula (12), a catalyst generally used in an enethiol reaction (such as a radical generator represented by azobisisobutyronitrile) can be used.
[0028] From the standpoint of ease of treating silica with an organosilicon compound having an imidazole group, it is preferred that the silica to be treated has a silanol group.
[0029] The bile acid adsorbent of the present invention can be obtained by treating silica with the above-mentioned organosilicon compound having an imidazole group. The silica treatment method may be a general method, but a wet method that allows uniform treatment is preferred.
[0030] The amount of the organosilicon compound having an imidazole group to be used for the treatment is not particularly limited, but is preferably 0.001 to 20 parts by mass, more preferably 0.01 to 15 parts by mass, relative to 100 parts by mass of silica. If the amount is less than 0.001 part by mass, the expected effect may be insufficient, and if the amount exceeds 20 parts by mass, it is not preferable from the viewpoint of cost.
[0031] The solvent used for dispersing silica in wet method is not particularly limited as long as it is a polar solvent that silica can be easily dispersed in.Such polar solvents include water; alcohols such as methanol, ethanol, isopropanol, etc.; ethers; ketones, etc., and from the viewpoint of reacting silica particles with the organosilicon compound having imidazole group, the solvent containing water is preferred. In order to improve the stability and dispersibility of the silica particles, a small amount of a surfactant, a polar solvent, etc. may be added.
[0032] There is no limitation on the temperature for the silica treatment, but from the viewpoint of reactivity, it is preferable to heat the mixture, and it is preferable to carry out the reaction at 40 to 60° C. for 1 to 10 hours.
[0033] After the reaction, the silica is taken out by filtering through a filter paper or the like, and the remaining solvent is removed by drying under reduced pressure to obtain silica treated with an organosilicon compound having an imidazole group. The obtained silica has an organosilicon compound having an imidazole group introduced on at least a part of the particle surface.
[0034] The bile acid adsorbent of the present invention can be incorporated into preparations used for the prevention and treatment of lifestyle-related diseases such as obesity, type II diabetes, hyperlipidemia, and fatty liver, inflammatory bowel disease, intestinal mucosal disorders, and colon cancer. In this case, pharma- ceutically acceptable ingredients such as ordinary carriers, binders, stabilizers, excipients, diluents, pH buffers, disintegrants, isotonicity agents, additives, coating agents, solubilizers, lubricants, glidants, solubilizing agents, lubricants, flavoring agents, sweeteners, solvents, gelling agents, and nutrients may be further added. Specific examples of these compounding ingredients include water, saline, animal fats and oils, vegetable oils, lactose, starch, gelatin, crystalline cellulose, gum, talc, magnesium stearate, hydroxypropyl cellulose, polyalkylene glycols, polyvinyl alcohol, glycerin, and the like.
[0035] The preparation containing the bile acid adsorbent of the present invention is preferably in the form of tablets, capsules, etc. having an enteric coating for the purpose of protecting the preparation from gastric acid or protecting the gastric mucosa from irritation to the stomach wall.
[0036] The enteric coating can be carried out by a general method such as the method described in Japanese Patent No. 3628401. Specifically, this method involves stirring a granular or finely divided solid drug in a centrifugal fluid coating device while spraying a liquid plasticizer or liquid, or a liquid wax that has been heated and melted, and then spraying an enteric coating agent onto the solid drug.
[0037] Examples of enteric coatings include cellulose acetate phthalate, cellulose acetate trimetate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, carboxymethylethylcellulose, and other celluloses; polyvinyl alcohol acetate phthalate; and copolymers of methacrylic acid and ethyl acrylate.
[0038] Among the above-mentioned enteric coatings, enteric methylcelluloses such as hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, and carboxymethylethylcellulose are preferred from the viewpoints of pH responsiveness and hydrolysis resistance.
[0039] The administration route of the bile acid adsorbent of the present invention is preferably oral, and the dosage is appropriately determined depending on the age, body weight, sex, symptoms, drug sensitivity, etc. Usually, the dosage range is 1 μg to 200 mg / day, preferably 2 μg to 2,000 μg / day, more preferably 3 to 200 μg / day, and even more preferably 4 to 20 μg / day, and is administered once or multiple times (e.g., 2 to 4 times) per day, but the dosage may be adjusted depending on the improvement of symptoms.
[0040] The method and form of ingestion of the health food containing the bile acid adsorbent of the present invention are free and are not particularly limited. For example, the health food containing the bile acid adsorbent of the present invention can be eaten as a meal replacement or between-meal snack. In this case, the bile acid adsorbent can be mixed with at least one selected from the group consisting of rice flour, buckwheat flour, udon flour, wheat flour, and bread crumbs, and used in regular cooking. These can also be processed into confectionery, buckwheat, udon, pasta, bread, etc. Furthermore, the health food may be in any state, such as a solid (powder or granules), jelly, liquid, or suspension, and may contain various ingredients such as sweeteners and acidulants.
[0041] Supplements containing the bile acid sequestrant of the present invention can be used in the same manner as commercially available supplements that suppress fat absorption. The ingredients to be added to the supplement containing the bile acid adsorbent of the present invention are not particularly limited.Specific examples of the ingredients include commonly used ingredients such as wheat starch, rice starch, corn starch, lactose, maltose, white sugar, glucose, gelatin, and vegetable oil.
[0042] Furthermore, the supplement containing the bile acid adsorbent of the present invention may be in the form of a tablet, capsule, liquid, powder, or soft capsule, and can be produced according to a conventional method for producing a supplement. EXAMPLES
[0043] The present invention will be specifically described below with reference to Synthesis Examples, Examples and Comparative Examples, but the present invention is not limited to the following Examples.
[0044] [1] Synthesis of organosilicon compounds [Synthesis Example 1] According to the method disclosed in JP-A-5-39295, an organosilicon compound represented by the following formula (3-1) was synthesized from 2-methylimidazole and 3-chloropropyltrimethoxysilane.
[0045] [ka]
[0046] [Synthesis Example 2] According to the method disclosed in Japanese Patent No. 3555845, an organosilicon compound represented by the following formula (4-1) was synthesized from 2-methylimidazole and 3-isocyanatopropyltrimethoxysilane.
[0047] [ka]
[0048] [Synthesis Example 3] According to the method disclosed in JP-A-05-186479, a mixture of organosilicon compounds represented by the following formulae (5-1), (7-1), and (8-1) was synthesized from 2-methylimidazole and 3-glycidoxypropyltrimethoxysilane.
[0049] [ka]
[0050] [Synthesis Example 4] According to the method disclosed in Japanese Patent No. 3523804, an organosilicon compound represented by the following formula (6-1) was synthesized from 2-methylimidazole and 3-methacryloxypropyltrimethoxysilane.
[0051] [ka]
[0052] [Synthesis Example 5] According to the method disclosed in Japanese Patent No. 4372461, a mixture of organosilicon compounds represented by the following formulas (7-1), (9-1), (10-1), and (13) was synthesized from 2-methylimidazole, 3-glycidoxypropyltrimethoxysilane, and 3-isocyanatopropyltrimethoxysilane.
[0053] [ka]
[0054] [Synthesis Example 6] According to the method disclosed in Japanese Patent No. 3555802, an organosilicon compound represented by the following formula (11-1) was synthesized from 1-vinyl-2-methylimidazole and 3-mercaptopropyltrimethoxysilane.
[0055] [ka]
[0056] [Synthesis Example 7] According to the method disclosed in Japanese Patent No. 3555802, an organosilicon compound represented by the following formula (12-1) was synthesized from 2-methyl-1-allylimidazole and 3-mercaptopropyltrimethoxysilane.
[0057] [ka]
[0058] [2] Preparation of bile acid adsorbents consisting of silica particles bonded with organosilicon compounds [Examples 1 to 7] 100 parts by mass of a mixture of water and methanol at a ratio of 1:9 (by mass) and 30 parts by mass of silica (Nipsil NS-KR, manufactured by Tosoh Silica Corporation) were mixed at 25° C., and 3 parts by mass of each of the organosilicon compounds obtained in Synthesis Examples 1 to 7 were added thereto, followed by stirring for 4 hours at 50° C. After stirring was completed, the solvent was filtered, washed with methanol, and then dried under reduced pressure at 110° C. for 1 hour to obtain a bile acid adsorbent consisting of silica particles to which the organosilicon compound was bonded.
[0059] The bile acid adsorption rate and water-supply swelling property were measured and evaluated according to the following procedures for each of the bile acid adsorbents obtained in Examples 1 to 7. The results are shown in Table 1.
[0060] [Measurement of bile acid adsorption rate] (1) As a bile acid sample, 0.1 g of commercially available glycolic acid was dissolved in 1 L of pH 8 Tris buffer to prepare a glycolic acid solution (100 μmol / L). (2) The glycolic acid solution was mixed with 100 mg of the bile acid adsorbent obtained in Examples 1 to 7, and the mixture was shaken and centrifuged. The glycolic acid concentration in the supernatant was calculated from the absorbance to determine the bile acid adsorption rate.
[0061] [Evaluation of water absorption and swelling] A glycolic acid solution prepared in the same manner as in the above method for evaluating the bile acid adsorption rate was mixed with 100 mg of the bile acid adsorbent obtained in Examples 1 to 7, and the presence or absence of swelling of the bile acid adsorbent was visually confirmed. The results are also shown in Table 1.
[0062] The bile acid adsorption rate and water-supply swelling property were also measured and evaluated for the following Comparative Examples 1 and 2. The results are also shown in Table 1. [Comparative Example 1] Instead of 100 mg of the bile acid adsorbents obtained in Examples 1 to 7, 100 mg of untreated silica (Nipsil NS-KR, manufactured by Tosoh Silica Corporation) was used. [Comparative Example 2] Instead of 100 mg of the bile acid adsorbents obtained in Examples 1 to 7, 100 mg of a commercially available bile acid adsorbent (Colevain, manufactured by Mitsubishi Tanabe Pharma Corporation) was used.
[0063] [Table 1]
[0064] As shown in Table 1, the bile acid adsorbent of the present invention exhibited higher bile acid adsorption performance than the untreated silica of Comparative Example 1, and also did not swell when mixed with water. On the other hand, the colebine of Comparative Example 2 showed high bile acid adsorption performance, but was observed to swell due to water absorption.
Claims
1. A bile acid adsorbent comprising silica particles having an organosilicon compound represented by the following general formula (1) bonded thereto: [Formula 1] (In the formula, R 1 , R 2 and R 3 each independently represents a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, a vinyl group, a phenyl group, or a benzyl group; R 4 represents a group represented by the following general formula (2): 1 and R 3 may be bonded to form a benzene ring.) [chemical 2] (In the formula, A represents a linear or branched divalent linking group which may contain a heteroatom, a urethane bond, a urea bond, a thiourethane bond, and / or a thiourea bond; R 5 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms; R 6 each independently represents an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms, and n represents an integer of 1 to 3.
2. R 4 The bile acid adsorbent according to claim 1, wherein is any of groups represented by the following formulas (3) to (12): [C3] (In the formula, m represents an integer of 1 to 12; R 7 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, k represents an integer of 1 to 12, l represents an integer of 1 to 3, R 1 , R 2 , R 3 , R 5 , R 6 and n have the same meaning as above.)
3. A formulation comprising the bile acid adsorbent of claim 1 or 2 and an enteric coating.
4. 4. The formulation of claim 3, wherein the enteric coating comprises one or more members selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, and carboxymethylethylcellulose.
5. A food comprising the bile acid adsorbent according to claim 1 or 2.
6. A supplement comprising the bile acid adsorbent according to claim 1 or 2.
Citation Information
Patent Citations
Antilipemic agent
JP1985209523A
Surface-treating agent for metal
JP1993039295A
Method for controlling or reducing off-flavours in beverages using silanized silica filter media
JP2008523806A
JPP3523804B
JPP3555845B
